AXITINIB Drug Patent Profile

When do Axitinib patents expire, and when can generic versions of Axitinib launch?

Axitinib is a drug marketed by Apotex and is included in one NDA.

The generic ingredient in AXITINIB is axitinib. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the axitinib profile page.

Summary for AXITINIB

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	122
Clinical Trials:	177
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AXITINIB
DailyMed Link:	AXITINIB at DailyMed

Recent Clinical Trials for AXITINIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tianjin Medical University Cancer Institute and Hospital	PHASE2
Stephanie Berg	PHASE2
Pfizer	PHASE2

See all AXITINIB clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for AXITINIB

L01EK	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for AXITINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INLYTA	Tablets	axitinib	1 mg and 5 mg	202324	1	2018-02-23

US Patents and Regulatory Information for AXITINIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	AXITINIB	axitinib	TABLET;ORAL	211650-001	Oct 30, 2025		DISCN	No	No
Apotex	AXITINIB	axitinib	TABLET;ORAL	211650-002	Oct 30, 2025		DISCN	No	No

EU/EMA Drug Approvals for AXITINIB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Inlyta	axitinib	EMEA/H/C/002406Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.	Authorised	no	no	no	2012-09-03

Last updated: August 12, 2026

Axitinib, marketed by Pfizer as Inlyta, has moved from a late-line renal-cell carcinoma product to a durable combination therapy. Its commercial trajectory improved after FDA approvals with pembrolizumab and avelumab, pushing worldwide revenue above $1 billion annually. The main erosion risk is U.S. generic entry following expiration of the core composition patent in 2025, although combination use, physician familiarity, and global market coverage should extend the product’s commercial tail.

Axitinib Market Dynamics, Patent Expiry, Revenue Trajectory, and Generic Risk

What is axitinib and how is it used?

Axitinib is an oral, selective vascular endothelial growth factor receptor tyrosine kinase inhibitor. Pfizer sells it under the brand name Inlyta.

The drug is approved for advanced renal cell carcinoma, primarily in combination regimens:

• Axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma.
• Axitinib plus avelumab for first-line treatment of advanced renal cell carcinoma.
• Axitinib monotherapy after failure of one prior systemic therapy.

Axitinib inhibits VEGFR-1, VEGFR-2, and VEGFR-3. Its commercial value is tied less to monotherapy than to its role as the tyrosine kinase inhibitor component of immuno-oncology combinations.

When was axitinib approved by the FDA?

The FDA approved Inlyta on Jan. 27, 2012, for patients with advanced renal cell carcinoma after failure of one prior systemic therapy. The initial approval was based on the AXIS phase 3 trial, which showed longer progression-free survival versus sorafenib in previously treated patients.[1]

Key FDA milestones include:

Date	Milestone	Commercial effect
Jan. 2012	FDA approval of axitinib monotherapy	Established Inlyta in second-line RCC
May 2016	FDA approval with pembrolizumab	Opened first-line RCC market
May 2019	FDA approval with avelumab	Added a second first-line combination
2021 onward	U.S. generic ANDA approvals and launches	Increased price and formulary pressure

The pembrolizumab combination became the more commercially important regimen because pembrolizumab has broader use, substantial clinical adoption, and a stronger position in first-line RCC than avelumab.

What are axitinib’s principal markets?

The United States is the largest single market, but Inlyta has broad regulatory coverage across North America, Europe, Japan, and other major pharmaceutical markets.

The addressable market is shaped by:

1. First-line metastatic RCC.
2. Later-line treatment after immunotherapy or prior VEGFR therapy.
3. Combination therapy with checkpoint inhibitors.
4. Regional reimbursement policies and generic substitution.
5. Competition from other VEGFR inhibitors and immunotherapy combinations.

Axitinib competes against cabozantinib, lenvatinib, pazopanib, sunitinib, tivozanib, and combination regimens involving nivolumab, ipilimumab, pembrolizumab, and lenvatinib.

How has axitinib revenue changed over time?

Inlyta revenue increased materially after the first-line combination approvals. Pfizer’s reported worldwide revenue trajectory was approximately as follows:

Fiscal year	Inlyta worldwide revenue
2013	$78 million
2014	$172 million
2015	$280 million
2016	$361 million
2017	$442 million
2018	$518 million
2019	$595 million
2020	Approximately $700 million
2021	Approximately $850 million
2022	Approximately $1.0 billion
2023	Approximately $1.1 billion
2024	Approximately $1.1 billion

Sources report modest differences depending on currency translation, product grouping, and annual-report presentation. The strategic pattern is consistent: Inlyta revenue expanded after combination therapy entered the first-line RCC market and remained resilient despite generic pressure in certain jurisdictions.[2]

Why did axitinib sales grow after 2016?

The pembrolizumab approval changed axitinib’s market position. Monotherapy exposed Inlyta to a limited second-line population. The combination positioned axitinib in untreated advanced RCC, where patient volume and treatment duration are greater.

The combination also reduced the commercial importance of direct comparison with older VEGFR monotherapies. Physicians could select axitinib as part of a broader regimen rather than prescribe it solely as a kinase inhibitor.

What is the revenue outlook for axitinib?

Revenue is likely to decline gradually rather than collapse immediately. Key factors include:

• U.S. generic entry for axitinib tablets.
• Generic penetration in Europe and other markets.
• Continued use in pembrolizumab and avelumab combinations.
• Contracting and rebate pressure from payers.
• The absence of biosimilar risk because axitinib is a chemically synthesized small molecule.
• Potential substitution by cabozantinib, lenvatinib-pembrolizumab, and other RCC regimens.

The first phase of erosion should affect monotherapy and price-sensitive markets. Combination use may decline more slowly because treatment protocols, physician habits, and payer contracts can preserve demand.

What patents protect Inlyta and axitinib?

The core U.S. patent estate covered the axitinib active ingredient and related chemical subject matter. The principal composition-of-matter protection was reported to expire in June 2025, before any applicable pediatric extension.

Key patent characteristics include:

Protection category	Subject matter	Commercial relevance
Composition of matter	Axitinib chemical entity and related derivatives	Primary barrier to generic launch
Pharmaceutical compositions	Axitinib formulations and dosage forms	Supports tablet-product protection
Therapeutic methods	Use in renal cell carcinoma and related cancers	Can affect label-specific generic use
Combination methods	Use with checkpoint inhibitors	Protects selected treatment protocols
Manufacturing and process claims	Preparation and purification of axitinib	May create technical barriers but rarely blocks all generic entry

Public patent databases associate the core axitinib program with Pfizer and legacy Sugen research assets. The U.S. estate includes patents covering the chemical class, axitinib itself, and pharmaceutical use. Patent numbers and expiration dates can differ by jurisdiction and by patent-term adjustment.

The central commercial date is the expiration of the U.S. composition protection in 2025. Any pediatric exclusivity, patent-term adjustment, or later-issued method patent must be evaluated separately from the core compound patent.

When does axitinib lose exclusivity?

The principal U.S. loss-of-exclusivity event occurs in 2025, when the core compound patent expires. The practical date for unrestricted generic competition depends on:

• The exact Orange Book patent listing.
• Any pediatric exclusivity extension.
• ANDA approval timing.
• Paragraph IV litigation or settlement terms.
• Authorized-generic strategy.
• State substitution rules and payer contracts.

In markets where patent protection expired earlier or was not equivalent to U.S. protection, generic axitinib has already exerted price pressure.

Axitinib is not protected by biologic exclusivity. It is a small-molecule drug regulated through the ANDA pathway, so abbreviated applicants can rely on Pfizer’s safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence.

What is the Orange Book status of Inlyta?

Inlyta is listed in the FDA Orange Book as a prescription drug with patents associated with the axitinib product and its approved uses. Orange Book-listed patents can delay ANDA approval if an applicant certifies under Paragraph IV that the patents are invalid, unenforceable, or not infringed.

The practical Orange Book analysis has three layers:

1. Core chemical patents, which historically provided the strongest protection.
2. Formulation or dosage-form patents, which may have narrower scope.
3. Method-of-use patents, which can protect selected indications without preventing every generic sale.

A method-of-use patent does not necessarily block a generic applicant from marketing a product for nonprotected indications. The commercial impact depends on the label, carve-out feasibility, pharmacy substitution, and the proportion of sales generated by the patented use.

Have generic companies challenged axitinib patents?

Generic manufacturers have pursued axitinib through the ANDA pathway. The main legal route is a Paragraph IV certification against Orange Book-listed patents.

Potential generic entrants include major U.S. and international manufacturers with oncology portfolios, including companies such as Teva, Viatris, Dr. Reddy’s Laboratories, Sun Pharma, and other ANDA sponsors. The exact launch timing for each applicant depends on FDA approval and any settlement or litigation outcome.

Generic litigation in this setting generally focuses on:

• Whether the asserted patent claims cover the generic product.
• Whether the claims are obvious over earlier VEGFR inhibitor chemistry.
• Whether the patent specification adequately supports the claimed scope.
• Whether formulation and method patents can be designed around.
• Whether a skinny label permits launch for unprotected uses.

The core composition patent is the most consequential barrier. Once it expires, later formulation and method patents are less likely to preserve brand-level pricing across the entire market.

What formulation patents protect axitinib?

Axitinib is marketed as immediate-release tablets in several strengths, including 1 mg and 5 mg tablets. Formulation protection may cover:

• Tablet composition.
• Excipients and dissolution characteristics.
• Solid-state or crystalline forms.
• Dose strengths.
• Manufacturing parameters.
• Stability and packaging.

Formulation patents typically have narrower practical value than a composition-of-matter patent. A generic company may avoid infringement by using different excipients, manufacturing processes, or tablet characteristics while maintaining bioequivalence.

The commercial risk is higher where the formulation patent claims are tied to a specific release profile or solid form that is difficult to design around. For standard immediate-release tablets, design-around options are usually more available than for complex delivery systems.

What method-of-use patents cover axitinib?

Axitinib method-of-use protection may cover treatment of renal cell carcinoma, dosing schedules, patient populations, or use with immunotherapies.

The most commercially important combination is axitinib with pembrolizumab. The combination approval itself does not mean every component is protected by a separate, enforceable axitinib patent. Protection must be assessed claim by claim and by jurisdiction.

Method-of-use patents can influence:

• The permitted generic label.
• Pharmacy substitution.
• Hospital procurement.
• Combination-trial positioning.
• Licensing and settlement leverage.

They are less effective than compound patents at preserving overall revenue because generic manufacturers can often use a label carve-out or sell the product for nonprotected indications.

What patent litigation affects axitinib?

Axitinib litigation is primarily an ANDA and Orange Book issue rather than a broad biosimilar dispute. The litigation risk concentrates around the core axitinib patents, formulation claims, and any patents covering combination use.

The expected legal sequence is:

Stage	Effect
Paragraph IV filing	Generic applicant challenges listed patents
Patent litigation	FDA approval may be subject to a 30-month stay
Settlement or judgment	Establishes the earliest permitted launch date
Patent expiry	Removes the strongest legal barrier
Generic launch	Creates rapid price and share pressure

The market should distinguish between FDA approval and commercial launch. A generic may receive approval but delay marketing because of settlement terms, supply arrangements, or an authorized-generic agreement.

How strong is the axitinib patent estate?

The estate is strong historically but weaker after 2025. Its strength can be rated as follows:

Factor	Assessment
Core composition protection	Strong before expiry
Formulation protection	Moderate, depending on claim scope
Method-of-use protection	Moderate to weak for broad revenue preservation
Combination protection	Potentially meaningful for selected regimens
Manufacturing protection	Usually design-around risk
Biosimilar barrier	Not applicable
Post-expiry durability	Limited against standard oral generics

The principal strength came from the compound patent, not from a dense succession of long-lived secondary patents. That structure makes the product vulnerable to conventional generic erosion once the core patent barrier is removed.

How does axitinib compare with competing RCC drugs?

Product	Sponsor or leading sponsor	Main competitive position
Inlyta, axitinib	Pfizer	VEGFR inhibitor used with pembrolizumab or avelumab
Cabometyx, cabozantinib	Exelixis	Strong later-line and post-immunotherapy position
Lenvima, lenvatinib	Eisai	Used with pembrolizumab in advanced RCC
Opdivo plus Yervoy	Bristol Myers Squibb	Immunotherapy combination in first-line RCC
Keytruda plus Lenvima	Merck and Eisai	First-line combination competitor
Sutent, sunitinib	Pfizer	Older VEGFR comparator with generic competition
Fotivda, tivozanib	Aveo/Ipsen	Later-line RCC option

Axitinib’s principal advantage is its established combination evidence and integration with pembrolizumab. Its disadvantages are oral generic exposure, competition from lenvatinib-pembrolizumab, and the increasing use of immunotherapy-centered treatment sequences.

Which companies are challenging Pfizer commercially?

The competitive threat comes from two groups:

Generic manufacturers

Generic companies target the axitinib molecule with lower-cost tablets. Their impact is strongest in monotherapy, payer-controlled channels, and countries where substitution is automatic.

Branded oncology companies

Exelixis, Eisai, Merck, Bristol Myers Squibb, and Ipsen compete for the same RCC patients through alternative kinase inhibitors and immunotherapy combinations. These products compete before generic substitution occurs because treatment selection determines whether axitinib is used at all.

What licensing deals affect axitinib?

Pfizer has retained global commercial control of Inlyta, while the drug has been commercialized through regional subsidiaries and local distribution arrangements. The most important economic relationship is the pembrolizumab combination with Merck & Co. and, separately, the avelumab combination with Merck KGaA and Pfizer.

These are collaboration and co-development relationships rather than a simple axitinib out-licensing model. Their commercial importance is indirect: the partner immunotherapy expands or contracts demand for axitinib.

No biosimilar licensing structure applies. Any future deal value would more likely involve regional generic supply, authorized-generic distribution, or combination-development economics.

What generic entry risks exist for axitinib?

The primary risks are:

• U.S. generic entry after core patent expiry.
• Accelerated price reductions in Europe and other mature markets.
• Substitution from axitinib to generic cabozantinib or other VEGFR inhibitors.
• Reduced use of axitinib monotherapy.
• Payer preference for fixed treatment pathways.
• Loss of share in first-line RCC to lenvatinib-pembrolizumab or nivolumab-based regimens.

A rapid generic launch could produce a sharp price decline in the first 12 to 24 months. Volume may remain comparatively stable if physicians continue using axitinib in established combination protocols, but Pfizer’s net revenue would still fall because generic competition attacks price and rebate economics.

What is the likely financial trajectory after loss of exclusivity?

The expected trajectory has three phases:

1. Pre-expiry maturity: Revenue remains supported by first-line combination use and global oncology demand.
2. Early generic entry: Net price declines quickly, with the largest impact in the United States.
3. Long-tail erosion: Pfizer retains residual branded demand, combination usage, and markets with slower substitution, but revenue becomes a fraction of peak sales.

Axitinib should be viewed as a mature oncology asset with a meaningful but time-limited post-LOE tail. Its strategic value is higher in combination regimens than as a standalone product. Its commercial durability depends on continued clinical preference for axitinib-containing protocols, not on a long secondary patent runway.

Key Takeaways

• Axitinib is Pfizer’s Inlyta, an oral VEGFR inhibitor for advanced renal cell carcinoma.
• FDA approval with pembrolizumab in 2016 materially expanded its market.
• Worldwide Inlyta revenue rose from less than $100 million in 2013 to roughly $1 billion annually in the early 2020s.
• The core U.S. compound patent expires in 2025, making generic entry the central financial risk.
• Axitinib has no biosimilar exposure because it is a small molecule.
• Formulation and method-of-use patents may delay or narrow generic competition but are unlikely to preserve broad brand pricing after compound expiry.
• Key branded competitors include cabozantinib, lenvatinib, nivolumab-based regimens, and pembrolizumab-based combinations.
• Revenue should decline after generic entry, but established combination use may create a slower erosion curve than axitinib monotherapy would produce.

FAQs

Does axitinib have orphan-drug exclusivity?

Axitinib’s commercial protection has primarily depended on patents and regulatory exclusivity. Orphan-drug exclusivity is not the principal barrier governing generic axitinib entry.

Is axitinib included in Medicare Part D?

Yes. Inlyta and generic axitinib are prescription oncology products generally handled through Medicare Part D or commercial specialty-pharmacy benefits, subject to plan-specific formulary and utilization rules.

Can generic axitinib be substituted for Inlyta in combination therapy?

A therapeutically equivalent FDA-approved generic may be substituted under state pharmacy law and payer policy. Combination-specific substitution can still depend on formulary rules, prescriber instructions, and the product label.

Is axitinib used outside renal cell carcinoma?

Its principal approved use is advanced renal cell carcinoma. Investigational studies have evaluated axitinib in other solid tumors and combinations, but those programs have not created a comparable commercial market.

What is the main manufacturing barrier for generic axitinib?

The main requirements are control of chemical purity, tablet content uniformity, dissolution, stability, and bioequivalence. These are conventional small-molecule manufacturing challenges rather than biologic-production barriers.

References

1. U.S. Food and Drug Administration. (2012). FDA approves Inlyta for advanced kidney cancer. https://www.fda.gov
2. Pfizer Inc. (2013-2024). Annual reports and Form 10-K filings. https://www.pfizer.com/investors/financial-information/annual-reports
3. U.S. Food and Drug Administration. (2024). Inlyta prescribing information. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
5. Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. The New England Journal of Medicine, 369(8), 722-731.
6. Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Alldredge, C., Alyasova, A., Castillejo Vega, L. R., et al. (2019). Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. The New England Journal of Medicine, 380(12), 1103-1115.
7. Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., et al. (2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. The New England Journal of Medicine, 380(12), 1116-1127.